Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central nervous procedure, conolidine modulates alternate molecular targets. A Science Advancements research located that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, wh